Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stok Raporu

Piyasa değeri: US$66.1b

Regeneron Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Regeneron Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 11.7% ve 8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15% olacağı tahmin edilmektedir.

Anahtar bilgiler

11.7%

Kazanç büyüme oranı

11.70%

EPS büyüme oranı

Biotechs kazanç büyümesi25.4%
Gelir büyüme oranı8.0%
Gelecekteki özkaynak getirisi14.99%
Analist kapsamı

Good

Son güncelleme20 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • May 18

Regeneron: Time To Forget Fianlimab (Rating Upgrade)

Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 03

REGN: Expanding Immunology And Gene Therapy Will Support Future Upside

Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.
Anlatı Güncellemesi • Apr 19

REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects

Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.
Anlatı Güncellemesi • Apr 04

REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline

Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.
Anlatı Güncellemesi • Mar 21

REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks

Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.
Anlatı Güncellemesi • Mar 07

REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks

Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.
Yeni Anlatı • Mar 03

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.
Anlatı Güncellemesi • Feb 21

REGN: Fair Outlook As Future Pipeline And Spending Risks Remain

Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.
Anlatı Güncellemesi • Feb 06

REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating

Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.
Anlatı Güncellemesi • Jan 23

REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating

Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.
Anlatı Güncellemesi • Jan 09

REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks

Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.
Anlatı Güncellemesi • Dec 25

REGN: Future Pipeline And Spending Risks Likely To Pressure Shares

Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.
Anlatı Güncellemesi • Dec 11

REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks

Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.
Anlatı Güncellemesi • Nov 27

REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks

Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.
Analiz Makalesi • Nov 19

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...
Anlatı Güncellemesi • Nov 12

REGN: Positive Trial Results And Approval Will Drive Continued Momentum

Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.
Analiz Makalesi • Nov 09

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...
Anlatı Güncellemesi • Oct 28

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead

Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.
Anlatı Güncellemesi • Sep 18

Broad Pipeline And Global Access Will Build Future Success

Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:REGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202818,9405,7886,8997,04022
12/31/202717,5535,1336,0906,27726
12/31/202615,8804,0885,0555,69627
3/31/202614,9204,4233,7915,013N/A
12/31/202514,3434,5053,7654,979N/A
9/30/202514,2484,5783,8815,071N/A
6/30/202514,2144,4593,5564,744N/A
3/31/202514,0864,4992,9623,953N/A
12/31/202414,2024,4133,5394,421N/A
9/30/202413,8474,6553,3194,247N/A
6/30/202413,4894,3223,1844,071N/A
3/31/202413,1003,8583,9304,739N/A
12/31/202313,1173,9543,6684,594N/A
9/30/202313,0973,9914,3595,224N/A
6/30/202312,6714,2993,0044,739N/A
3/31/202312,3704,1832,5274,281N/A
12/31/202212,1734,3383,3985,015N/A
9/30/202213,7105,3704,1485,668N/A
6/30/202214,2275,6877,8698,452N/A
3/31/202216,5087,9347,9368,515N/A
12/31/202116,0728,0756,5297,081N/A
9/30/202113,5436,9965,3815,940N/A
6/30/202112,3846,2051,6942,272N/A
3/31/20219,1984,0042,0292,589N/A
12/31/20208,4973,5132,0042,618N/A
9/30/20207,9383,1561,5822,175N/A
6/30/20207,3872,9842,4252,986N/A
3/31/20207,0132,2791,7062,231N/A
12/31/20196,5582,116N/A2,430N/A
9/30/20196,6222,144N/A2,371N/A
6/30/20196,5422,069N/A2,267N/A
3/31/20196,5722,428N/A2,473N/A
12/31/20185,1462,444N/A2,195N/A
9/30/20186,3651,798N/A2,033N/A
6/30/20186,2031,591N/A1,995N/A
3/31/20186,0651,428N/A1,570N/A
12/31/20175,8721,199N/A1,307N/A
9/30/20175,5171,278N/A1,118N/A
6/30/20175,2361,155N/A1,354N/A
3/31/20174,979963N/A1,784N/A
12/31/20164,860896N/A1,486N/A
9/30/20164,732797N/A1,377N/A
6/30/20164,649743N/A1,619N/A
3/31/20164,435741N/A1,477N/A
12/31/20154,104636N/A1,331N/A
9/30/20153,808571N/A1,247N/A
6/30/20153,396444N/A519N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: REGN 'nin tahmini kazanç büyümesi (yıllık 11.7% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: REGN şirketinin kazançlarının (yıllık 11.7% ) US pazarından (yıllık 16.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: REGN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: REGN şirketinin gelirinin (yıllık 8% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: REGN şirketinin gelirinin (yıllık 8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: REGN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 04:49
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Regeneron Pharmaceuticals, Inc. 53 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jasper HellwegArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays